C-erbB-3 expression in non-small cell lung cancer (NSCLC) patients treated by Erlotinib.
Fiche publication
Date publication
janvier 2011
Journal
Anticancer research
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MASCAUX Céline
Tous les auteurs :
CsToth I, Anthoine G, Berghmans T, Mascaux C, Paesmans M, Sculier JP, Meert AP
Lien Pubmed
Résumé
The clinical impact of c-erbB-3 has seldom been assessed in patients with non small cell lung cancer (NSCLC).
Mots clés
Adenocarcinoma, drug therapy, Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, drug therapy, Carcinoma, Squamous Cell, drug therapy, ErbB Receptors, antagonists & inhibitors, Erlotinib Hydrochloride, Female, Humans, Immunoenzyme Techniques, Lung Neoplasms, drug therapy, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Staging, Prognosis, Protein Kinase Inhibitors, therapeutic use, Quinazolines, therapeutic use, Receptor, ErbB-3, metabolism, Survival Rate
Référence
Anticancer Res.. 2011 Jan;31(1):281-5